New hope for cervical cancer patients when immunotherapy fails
NCT ID NCT07186868
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a new drug combination for women with cervical cancer that has returned or spread and no longer responds to standard immunotherapy. About 25 participants will receive a dual-targeting immunotherapy plus chemotherapy, with or without an anti-growth drug, for up to 6 cycles followed by maintenance. The main goal is to see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.